北海道大学 · 医学
Hirata教授の研究室では、PET画像を用いたがんの生物学的特性の定量的評価に注力しています。特に、腫瘍の治療反応予測を高めるために、SUVの自動定義手法や、脳腫瘍における虚血状態の非侵襲的イメージング技術の開発を進めています。臨床応用に即した画像解析法の確立が目指されており、がん治療の個別化に貢献する研究が展開されています。
Figures are computed from collected data and may differ slightly.
Our semi-automated method could define the liver SUV robustly as the threshold value used for tumor volume measurements according to PERCIST. The method could avoid possible subjective bias of manual liver VOI placement and is thus expected to improve clinical performance of volume-based parameters for prediction of cancer treatment response.
Glioma is the most common malignant brain tumor. Hypoxia is closely related to the malignancy of gliomas, and positron emission tomography (PET) can noninvasively visualize the degree and the expansion of hypoxia. Currently, <sup>18</sup>F-fluoromisonidazole (FMISO) is the most common radiotracer for hypoxia imaging. The clinical usefulness of FMISO PET has been established; it can distinguish glioblastomas from lower-grade gliomas and can predict the microenvironment of a tumor, including necro
Positron emission tomography (PET) has unique characteristics for quantitative assessment of tumour biology in vivo. Accumulation of F-18 fluorodeoxyglucose (FDG) may reflect tumour characteristics based on its metabolic activity. Quantitative assessment of FDG uptake can often be applied for treatment monitoring after chemotherapy or chemoradiotherapy. Numerous studies indicated biochemical change assessed by FDG PET as a more sensitive marker than morphological change estimated by CT or MRI. I
Open papers in the app to read, cite, and organize with AI.
